7 research outputs found

    Cost Analysis of Neonatal In-Line Ex Vivo Point-of-Care Monitoring

    No full text
    A hypothetical model using a base case and sensitivity analyses compared averted and incurred costs of in-line monitoring with neonatal intensive care unit satellite laboratory testing. Data were obtained retrospectively for 1 year from 50 consecutive critically ill premature neonates weighing less than 1,000 g at birth whose blood tests were performed in-line and processed at the satellite laboratory. Averted costs included phlebotomies, satellite blood testing, and transfusions; incurred costs included in-line monitor rental, nursing time, and daily monitor validation. In-line monitoring led to cost savings of $324 per neonate and a benefit/cost ratio (BCR) of 1.23 in our base case. Sensitivity and scenario analyses addressed uncertainty and led to a BCR variation of 0.41 to 2.48. Compared with satellite laboratory testing, in-line monitoring of critically ill neonates may generate cost savings through reduced laboratory analysis expense, less phlebotomy loss, and fewer blood transfusions for hospitals with high laboratory cost structures. Because most cost savings result from offsetting indirect costs (eg, building space and hospital overhead) that are of a longer term nature, short-run cost savings are less likely to be realized

    Safety and immunogenicity of sequential rotavirus vaccine schedules

    No full text
    BACKGROUND AND OBJECTIVES: Although both licensed rotavirus vaccines are safe and effective, it is often not possible to complete the schedule by using the same vaccine formulation. The goal of this study was to investigate the noninferiority of the immune responses to the 2 licensed rotavirus vaccines when administered as a mixed schedule compared with administering a single vaccine formulation alone. METHODS: Randomized, multicenter, open-label study. Healthy infants (6-14 weeks of age) were randomized to receive rotavirus vaccines in 1 of 5 different schedules (2 using a single vaccine for all doses, and 3 using mixed schedules). The group receiving only the monovalent rotavirus vaccine received 2 doses of vaccine and the other 4 groups received 3 doses of vaccine. Serum for immunogenicity testing was obtained 1 month after the last vaccine dose and the proportion of seropositive children (rotavirus immunoglobulin A >20 U/mL) were compared in all the vaccine groups. RESULTS: Between March 2011 and September 2013, 1393 children were enrolled and randomized. Immune responses to all the sequential mixed vaccine schedules were shown to be noninferior when compared with the 2 single vaccine reference groups. The proportion of children seropositive to at least 1 vaccine antigen at 1 month after vaccination ranged from 77% to 96%, and was not significantly different among all the study groups. All schedules were well tolerated. CONCLUSIONS: Mixed schedules are safe and induced comparable immune responses when compared with the licensed rotavirus vaccines given alone.Fil: Libster, Romina Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación para la Investigación en Infectología Infantil; Argentina. Vanderbilt University; Estados UnidosFil: McNeal, Monica. Cincinnati Children's Hospital Medical Center; Estados UnidosFil: Walter, Emmanuel B.. Duke University School Of Medicine; Estados UnidosFil: Shane, Andi L.. University of Emory; Estados UnidosFil: Winokur, Patricia. University of Iowa; Estados UnidosFil: Cress, Gretchen. University of Iowa; Estados UnidosFil: Berry, Andrea A.. University of Maryland; Estados UnidosFil: Kotloff, Karen L.. University of Maryland; Estados UnidosFil: Sarpong, Kwabena. University of Texas Medical Branch; Estados UnidosFil: Turley, Christine B.. University of Texas Medical Branch; Estados UnidosFil: Harrison, Christopher J.. Children's Mercy Hospital; Estados UnidosFil: Pahud, Barbara A.. Children's Mercy Hospital; Estados UnidosFil: Marbin, Jyothi. Benioff Children's Hospital Oakland; Estados UnidosFil: Dunn, John. Group Health Cooperative; Estados UnidosFil: El-Khorazaty, Jill. Emmes Corporation; Estados UnidosFil: Barret, Jill. Emmes Corporation; Estados UnidosFil: Edwards, Kathryn M. Vanderbilt University; Estados Unido
    corecore